Multiple Sclerosis, Primary Progressive

Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is injection, for intravenous use. Initial U.S. Approval: 2017